Document Detail

The Role of Systemic Chemotherapy in Management of Upper Tract Urothelial Cancer.
MedLine Citation:
PMID:  23344684     Owner:  NLM     Status:  Publisher    
Upper tract urothelial cancer (UTUC) accounts for roughly 5 % of all urothelial cancers. At presentation, 30 % of patients demonstrate invasive and/or locally advanced disease, 30-40 % have regional lymph node involvement, and 20 % harbor metastatic disease. Systemic recurrence and progression rates after surgery for patients with advanced disease range between 45-60 %. Five-year cancer specific survival rates for pT2 and pT3 tumors are 73 % and 40 %, respectively. Median survival for patients with pT4 disease is approximately 6 months. Nonetheless, there is a lack of improvement in the rates of systemic recurrence and progression in patients with advanced UTUC. Extrapolating evidence obtained from experience with multi-modal therapy of patients with urothelial bladder cancer, additional improvements in oncological outcomes for patients with UTUC can be achieved through integration of effective systemic chemotherapy with local tumor control. We provide an overview of the rationale and utilization strategies of peri-operative systemic chemotherapy in patients with UTUC.
Bishoy A Gayed; Gregory R Thoreson; Vitaly Margulis
Related Documents :
16520464 - Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for p...
23991294 - Re-administration after the failure of gefitinib or erlotinib in patients with advanced...
17080234 - Outcome of metastatic gist in the era before tyrosine kinase inhibitors.
3065734 - Bone marrow biopsy in chronic lymphocytic leukemia.
9504724 - Present status of induction treatment in stage iiia-n2 non-small cell lung cancer: a re...
12414034 - Pulmonary blastoma: report of five cases and identification of clinical features sugges...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-24
Journal Detail:
Title:  Current urology reports     Volume:  -     ISSN:  1534-6285     ISO Abbreviation:  Curr Urol Rep     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-24     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100900943     Medline TA:  Curr Urol Rep     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
University of Texas Southwestern Medical Center, Dallas, TX, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Conservative Nephron-Sparing Treatment of Upper-Tract Tumors.
Next Document:  Evaluation of Renal Masses with Contrast-Enhanced Ultrasound.